Background and Purpose-Previous studies examining genetic associations with MRI-defined brain infarct have yielded inconsistent findings. We investigated genetic variation underlying covert MRI infarct in persons without histories of transient ischemic attack or stroke. We performed meta-analysis of genome-wide association studies of white participants in 6 studies comprising the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. Methods-Using 2.2 million genotyped and imputed single nucleotide polymorphisms, each study performed crosssectional genome-wide association analysis of MRI infarct using age-and sex-adjusted logistic regression models. 2 Although the majority of these MRI infarcts do not produce acute clinical symptoms leading to a diagnosis of stroke, they cannot be considered benign, silent, or asymptomatic, because they are associated with an increased risk for cognitive deficits, motor impairments, and future stroke. 2 The pathogenesis of these covert brain infarcts remains poorly understood.
Study-specific findings were combined in an inverse-variance-weighted meta-analysis, including 9401 participants with mean age 69.7 (19.4% of whom had Ն1 MRI infarct). Results-The most significant association was found with rs2208454 (minor allele frequency, 20%), located in intron 3 of MACRO domain containing 2 gene and in the downstream region of fibronectin leucine-rich transmembrane protein 3 gene. Each copy of the minor allele was associated with lower risk of MRI infarcts (odds ratio, 0.76; 95% confidence interval, 0.68 -0.84; Pϭ4.64ϫ10
Ϫ7
). Highly suggestive associations (PϽ1.0ϫ10 Ϫ5 ) were also found for 22 other single nucleotide polymorphisms in linkage disequilibrium (r 2 Ͼ0.64) with rs2208454. The association with rs2208454 did not replicate in independent samples of 1822 white and 644 black participants, although 4 single nucleotide polymorphisms within 200 kb from rs2208454 were associated with MRI infarcts in the black population sample. Key Words: brain infarction Ⅲ cohort study Ⅲ genome-wide association study Ⅲ meta-analysis V ascular disease of the brain is a leading cause of long-term disability and death. The burden of brain vascular disease is far greater than suggested by occurrence of acute neurological events such as stroke. 1 Brain imaging techniques, especially MRI, have revealed that brain infarcts are common in the elderly, especially small subcortical infarcts. 2 Although the majority of these MRI infarcts do not produce acute clinical symptoms leading to a diagnosis of stroke, they cannot be considered benign, silent, or asymptomatic, because they are associated with an increased risk for cognitive deficits, motor impairments, and future stroke. 2 The pathogenesis of these covert brain infarcts remains poorly understood.
Conclusions-This
Whereas several monogenic disorders are known to cause brain infarcts, the genes underlying brain infarcts in the general population remain undetermined. 3 A genetic component is suggested by increased risk of covert MRI infarcts among individuals whose parents or siblings have experienced clinically overt infarcts. 4, 5 Previous candidate gene studies of covert MRI infarcts have yielded inconsistent findings. Genome-wide association studies (GWAS) of MRI infarcts are lacking and would permit an unbiased search for genetic variants associated with this phenotype, without relying on a priori hypotheses about underlying pathophysiology. 6 To study genetics of these infarcts, we adapted an analytic approach used in a previous study 7 of stroke from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium and combined GWAS from 6 prospective population-based cohort studies: the Aging GeneEnvironment Susceptibility-Reykjavik Study (AGESReykjavik); the Atherosclerosis Risk in Communities (ARIC) Study; the Austrian Stroke Prevention Study (ASPS); the Cardiovascular Health Study (CHS); the Framingham Heart Study (FHS); and the Rotterdam Study. We present results from this meta-analysis that included 9401 stroke-free white participants.
Materials and Methods

Consortium
The CHARGE consortium includes large prospective communitybased cohort studies having genome-wide variation data coupled with extensive data on multiple phenotypes. 8 All participating studies agreed on phenotype harmonization, covariate selection, prespecified analytic plans for within-study analyses, and meta-analysis of results. Each study secured approval from Institutional Review Boards, and all participants provided written informed consent for study participation, MRI scanning, and use of DNA for genetic research.
Setting
Details of cohort selection, risk factor assessment, and outcome determination in the 6 studies have been reported previously (supplemental Appendix, section 1, available online at http://stroke.ahajournals.org). Briefly, the AGES-Reykjavik Study is a single-center, prospective continuation of the Reykjavik Study, which included persons born 1907 to 1935 and living in Reykjavik, Iceland, in 1967, when the study was started. In 2002 to 2006, 5764 participants from the cohort were reexamined as a part of the AGES-Reykjavik Study. 9 The ARIC study enrolled adults aged 45 and 64 years, from 4 US communities (Nϭ15 792, including 11 478 whites). The baseline examination was in 1987 to 1989. 10 The ASPS enrolled 2007 inhabitants of Graz, Austria, who lacked neuropsychiatric disease. Between 1991 and 1994 and 1999 and 2003, an extended diagnostic work-up including neuroimaging was performed in a subset of participants aged 45 to 85 years. 11, 12 The CHS enrolled adults who were 65 years or older and from 4 US communities (Nϭ5888, including 4925 whites). The baseline examination was either in 1989 to 1990 or 1992 to 1993. 13 The FHS is a US-based, single-site study that comprises 3 generations of participants. Members of the original cohort followed-up since 1948 (Nϭ5209), 14, 15 and the members of the offspring cohort followed-up since 1971 (Nϭ5124), 14 were invited to undergo an initial brain MRI in 1999 to 2005. The Rotterdam Study enrolled inhabitants from a district of Rotterdam (Ommoord), The Netherlands, aged 55 years or older (Nϭ7983), at the baseline examination in 1990 to 1993 (Rotterdam Study I). 16 In 2001, the Rotterdam Study cohort was expanded by 3011 newly eligible persons (Rotterdam Study II).
MRI Scans
In each study, eligible participants were invited to undergo MRI scans, which were performed and interpreted in a standardized fashion without knowledge of demographic or clinical information (supplemental Appendix, section 2). Infarct on MRI scan was defined as an area of abnormal signal intensity in a vascular distribution that lacked mass effect. Infarcts had to be Ն3 to 4 mm. Efforts were made in all studies to distinguish infarcts from dilated perivascular spaces. All participants were categorized as having or not having at least 1 MRI infarct.
Genotyping
The consortium was formed after individual studies had finalized their GWAS platforms, which differed across studies. All studies used their genotype data to impute to the 2.5 million nonmonomorphic, autosomal, single nucleotide polymorphisms (SNP) described in HapMap's European population panel. Extensive quality control analyses were performed in each cohort. Because the top SNP was imputed in all of the cohorts, we directly genotyped it in studies in which the quality of imputation was judged to be poor. Details on the genotyping, imputation, and quality control efforts can be found elsewhere (supplemental Appendix, section 3).
Study Population
Participants were eligible for these analyses if they had genotyping, an MRI, and lacked a history of transient ischemic attack or stroke before their MRI (covert MRI infarcts). Participants were entirely or almost entirely European whites in the AGES-Reykjavik Study, ASPS, FHS, and Rotterdam Study, so black participants from ARIC and CHS were not included in these analyses. In addition, CHS did not genotype participants with any form of clinical cardiovascular disease at baseline. By design, ASPS did not perform MRI scans in patients with transient ischemic attack or stroke. Also, ASPS and Rotterdam Study did not perform MRI scans in participants with dementia. The number and characteristics of participants from each cohort are shown in Table 1 .
Statistical Analyses Within Studies
Each study fit an additive genetic model with a 1-degree-of-freedom trend test relating genotype dosage, 0 to 2 copies of the minor allele, to having or not having at least 1 MRI infarct. We used logistic regression models to calculate odds ratios (OR) with corresponding 95% confidence intervals (CI). Initial analyses were adjusted only for age and sex to avoid adjusting for covariates that might lie along a causal pathway. In addition, ARIC and CHS also adjusted for study site, and FHS adjusted for familial structure. To explore potential mechanisms, we additionally adjusted our most significant association in one model for systolic blood pressure and in another model for the presence or absence of hypertension, defined as systolic blood pressure Ն140 mm Hg, diastolic blood pressure Ն90 mm Hg, or use of antihypertensive medications. 17 All studies screened for latent population substructure, which was negligible (supplemental Appendix, section 4).
Meta-Analysis
We conducted a fixed-effects meta-analysis of results from the 6 studies, with 7 cohorts counting the Rotterdam Study II, using inverse-variance weighting. After quality control, filtering, and imputation within each study, we restricted our meta-analysis to 2 217 889 autosomal SNP that were common to all studies and had an average minor allele frequency Ͼ2%. Details on the meta-analysis strategy and functional annotation of SNP are available (supplemental Appendix, section 5). As suggested by others, 6 we decided a priori on a genome-wide significance threshold of 5ϫ10 Ϫ8 . SNP with 5ϫ10
Ϫ8 ϽPϽ1ϫ10 Ϫ5 were considered highly suggestive associations. As available in meta-analysis, we also examined associa- *Definition of baseline characteristics was uniform across all studies. Hypertension was defined using standard criteria 17 as systolic blood pressure Ն140 mm Hg, diastolic blood pressure Ն90 mm Hg, or being on antihypertensive treatment; diabetes mellitus was defined as a casual or 2 hours postprandial blood glucose Ն200 mg/dL (11 mmol/L), a fasting blood glucose Ն126 mg/dL (7 mmol/L), or use of insulin or oral hypoglycemic agents; CVD (cardiovascular disease) was defined as presence of congestive heart failure, coronary heart disease, or intermittent claudication.
†In ASPS and CHS, participants with prevalent TIA or stroke were not included. In CHS, participants with other prevalent CVD were also not included. ‡In ASPS and Rotterdam studies, participants with dementia did not undergo cranial MRI.
tions with candidate SNP, or their proxies, previously reported to be significantly associated with covert MRI infarcts.
Replication
We attempted to replicate findings for our top SNP by genotyping it in 1822 elderly white participants from the 3C-Dijon study 18, 19 and 644 black participants from the ARIC study. 10 We also explored 59 SNP within 300 kb of our top SNP using in-silico replication in the black sample (supplemental Appendix, section 7). 10 We set the threshold for replication at 1-sided Pϭ0.05.
Results
Among 9401 participants whose mean age was 69.7 years and 53.4% women, 1822 (19.4%) had at least 1 MRI infarct (Table 1) . After meta-analysis the genomic inflation factor was 0.996, indicating no significant inflation of probability values. Figure 1 shows the genome-wide plot of probability values for individual SNP against their genomic position. None of the peaks cleared the threshold for genome-wide significance, but 51 SNP had highly suggestive associations, with PϽ1ϫ10 Ϫ5 (Table 2 , supplemental Appendix, section 6, Table I ). There was no significant heterogeneity across studies for the association with these SNP (supplemental Appendix, section 6).
The most significant association was found on chromosome 20p12 with SNP rs2208454, located in intron 3 of Figure 2 shows a forest plot of risk estimates for rs2208454 across the 7 cohorts. Twenty-two other SNP in intron 3 of MACROD2 were also associated with MRI infarcts, with PϽ1.0ϫ10 Ϫ5 ( Table 2 , supplemental Appendix, Table I ). All were in linkage disequilibrium with rs2208454: r 2 Ͼ0.64 for all and r 2 Ͼ0.8 for 17 of the SNP. Of these 22 SNP, 1 was intronic within FLRT3 (rs6110247) and 3 were potential transcription factor binding sites (rs6110247, rs743216, and rs3789335). Figure 3 shows all SNP within a 200-kb region on either side of the top hit, together with probability values, recombination rates, and known genes in that region.
Although estimated quality of imputation for rs2208454 was excellent in most studies (observed/expected ͓O/E͔ ratio, Ͼ0.95), it was poor in CHS (O/E ratio, 0.48). Therefore, rs2208454 was genotyped in CHS. When incorporating this result in the meta-analysis instead of the imputed data, the OR was the same at 0.76, but the probability value was smaller at 1.44ϫ10
Ϫ7
. We failed to replicate findings for the top SNP either in 1822 white participants from 3C-Dijon for whom mean age was 72.5 years and 9.4% had at least 1 MRI infarct (minor allele frequency, 22%; OR, 0.99; 95% CI, 0.76 -1.29; Pϭ0.92) or in 644 black participants from the ARIC study, for whom mean age was 61.5 years and 15.5% had at least 1 MRI infarct (minor allele frequency, 6.5%; OR, 1.26; 95% CI, 0.74 -2.15; Pϭ0.40). However, 4 other SNP in intron 3 of MACROD2 within 50 to 151kb from rs2208454 were significantly associated with MRI infarcts in the black sample (rs7268327, Pϭ0.045; rs1998237, Pϭ0.006; rs4464346, ; dashed blue line, more liberal threshold for genome-wide significance also used in the literature. Pϭ5.0ϫ10 Ϫ7 ; dotted red line, threshold for highly suggestive associations, Pϭ1.0ϫ10
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Pϭ0.0006; rs8116105, Pϭ0.01). In the discovery sample, rs8116105 was also associated with MRI infarcts, although the direction of the association was opposite (Pϭ0.02; supplemental Appendix, Table II ). The linkage disequilibrium pattern in this region differs substantially between white and black populations ( Figure 4 ). Details on the replication effort are contained in the supplemental Appendix, section 7. We repeated these analyses including, rather than excluding, participants with a history of a transient ischemic attack or stroke (Table 1) . The results were similar, although the associations were slightly weaker in general (data not shown). We also examined associations with previously reported candidate SNP, or their proxies, none of which was significant after correction for multiple testing (supplemental Appendix, section 9). In addition, we examined associations with top SNP in the Ninjurin-2 gene associated with ischemic stroke in a recent CHARGE GWAS meta-analysis 7 and found none significantly associated with MRI infarcts. Finally, we explored relations between ischemic stroke and the 23 SNP in MACROD2 (Table 2) in the recent CHARGE GWAS metaanalysis of ischemic stroke. 7 No significant association of these SNP with ischemic stroke was identified.
Discussion
This meta-analysis of GWAS data on covert MRI-defined brain infarcts included 9401 participants without a history of transient ischemic attack or stroke from 6 community-based studies. The most significant association (Pϭ4.64ϫ10 Ϫ7 ) was found for SNP rs2208454 on chromosome 20p12, located in intron 3 of MACROD2 and in the downstream region of FLRT3. The less common allele was associated with a lower risk. Twenty-two SNP in linkage disequilibrium with rs2208454 were also associated with MRI infarcts, with PϽ1.0ϫ10 Ϫ5 , as were 28 other SNP in 8 different loci. No association reached our preset threshold for genome-wide significance of 5.0ϫ10
Ϫ8 . In 2 replication samples of 1822 white participants from 3C-Dijon and 644 black participants from ARIC, we did not observe an association with rs2208454, although 4 SNP within 200 kb from rs2208454 were associated with MRI infarcts in the black sample. Finally, we did not observe an association with SNP previously reported to be associated significantly with covert MRI infarcts in candidate genes studies. The reference SNP number (rs), function, and chromosome (chr) position are listed. OR, 95% CI, and P as powers of 10 (E) are based on the meta-analysis. Each row lists only the SNP phenotype association with the lowest P for that locus. The last column shows the number of additional SNP at the same locus, within 250 kb of the specified SNP, that were also associated with the phenotype with a PϽ10
Ϫ5
. Complete details for these additional SNP are provided online in Table I . Alleles were identified based on the plus strand of the NCBI build 36. The minor allele was also the coded allele, and minor allele frequency (MAF) is based on allele frequency in meta-analysis sample. The Appendix, section 8, has details on calculating the population-attributable risk (PAR). For SNP whose minor allele had an inverse association with MRI infarcts (OR, Ͻ1.0), the PAR has been calculated using the major allele as the risk allele. The Human Gene Organization (HUGO) Gene Nomenclature System symbols is used for the 2 genes located closest to each SNP, and the distance of the associated SNP from the 5Ј end (start) or 3Ј end (stop) of the gene (the closest of the 2). Standardized gene annotations for all SNP results were derived programmatically from the UCSC Genome Browser RefSeq gene track (hg18). Distances to genes are given in kilobase (kb) pairs, based on NCBI build 36. The function of the protein encoded by MACROD2 is poorly understood. It contains a macro domain that is evolutionarily conserved and expressed in fetal and adult human brain. 20, 21 Macro domains bind ADP-ribose, suggesting a role in ADP-ribosylation, a post-translational modification involved in many processes including DNA repair, transcriptional activation, and repression, and telomere and chromatin biology. 22 Nested in intron 3 of MACROD2, FLRT3 encodes Ϫ5 in meta-analysis, and 4 SNP with PϽ0.05 in black sample, using HapMap release 22. Plot on top depicts LD in European population (CEU), whereas plot on bottom depicts LD in black population (YRI). The color scheme is white for DЈϽ1 and logarithm of odds (LOD)Ͻ2, blue for DЈϭ1 and LODϽ2, shades of pink and red for DЈϽ1 and LODՆ2, and bright red for DЈϭ1 and LODՆ2. The SNP marked in red is rs2208454, the 4 SNP marked in blue are SNP with PϽ0.05 in the black sample; from left to right: rs7268327, rs1998237, rs4464346, and rs8116105. LD could not be measured for 3 SNP in the YRI population because of a minor allele frequency Ͻ0.001 (rs6135125, rs6110247, rs12624446). Green lines represent genes in region.
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fibronectin leucine-rich transmembrane protein 3. 23 The gene is expressed in various tissues, including brain, and is well-conserved across species. 24 The protein it encodes modulates homotypic cell adhesion and promotes fibroblast growth factor signaling, 24 which is potentially involved in angiogenesis and neurogenesis. 25 In animal experiments, FLRT3 was shown to promote neurite outgrowth after axonal injury. 26, 27 Intriguingly, even though both FLTR3 and Ninjurin-2 appear to modulate response to neuronal injury, the Ninjurin-2 SNP identified in the recently published ischemic stroke GWAS within the CHARGE consortium were not significantly associated with covert MRI infarcts, and the MACROD2 SNP identified through the present analysis were not associated with overt ischemic stroke. A possible explanation for this discrepancy could be that MRI infarcts comprise mainly small subcortical infarcts, whereas ischemic stroke represents a much more heterogeneous entity. Further investigations are needed, beginning with replication of the associations in external cohorts of MRI-defined infarcts, ischemic stroke, and subtypes of ischemic stroke.
None of the 23 SNP in MACROD2 with PϽ10 Ϫ5 was significantly associated with gene expression in publicly available genome-wide expression quantitative trait loci data sets (supplemental Appendix, section 6), but this finding should be interpreted cautiously because less than half of these SNP were present on any of the genotyping arrays used in these studies and expression quantitative trait loci may be tissue and insult specific.
This meta-analysis has strengths. It included 6 large cohort studies with similar MRI protocols. The analyses were restricted to white participants to minimize the risk of population stratification. Genotyping was subjected to rigorous quality control. Our study also has limitations. Despite having close to 10 000 participants, of whom almost 2000 had covert MRI infarcts, we had limited power to detect associations with small effect sizes and associations with rare variants. An important caution is that the association with the top SNP was not directly replicated in 2 independent samples. Hence, we cannot exclude the possibility that this association was a chance finding. However, the power to detect an association with rs2208454 in the 2 replication samples was relatively low (61% for the white participants from 3C-Dijon and 18% for the black participants from ARIC), assuming the same effect size as in the discovery sample, which is likely an overestimation. 28 The definition of infarcts may also have differed across discovery and replication cohorts, especially concerning the discrimination of infarcts from enlarged perivascular spaces. Furthermore, identified SNP may not be the causal variants but merely markers in linkage disequilibrium with causal variants. Substantial differences in linkage patterns between whites and blacks could result in different markers being in linkage disequilibrium with the causal variant in the 2 populations. Interestingly, 4 SNP located in the same locus as rs2208454 were associated with MRI infarcts in the black sample. Although these exploratory results do not provide direct replication, because these SNP were in weak linkage disequilibrium with rs2208454, they suggest that the locus may be worthy of further exploration. If replication can be obtained in the future, including in black samples, then the latter perhaps could help refine the signal and prove useful for the identification of a causal variant. Finally, even though the studies included in the meta-analysis are population-based, the samples are not perfectly representative of the total cohort, because they include subsets of individuals who were able to undergo brain MRI and agreed to do so.
Conclusion
This meta-analysis of GWAS shows highly suggestive association of covert MRI infarcts with rs2208454 on chromosome 20p12 (Pϭ4.64ϫ10 Ϫ7 ). Attempted replication of the top SNP in an independent white sample failed, and additional attempts in larger samples to replicate this finding and associations with other suggestive loci are needed. Extending replication efforts not only in white but also in black populations may prove useful for fine mapping purposes. The molecular, clinical, and epidemiological correlates of confirmed associations may permit new insights into the pathophysiology and prevention of covert brain infarcts. 
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